Context Therapeutics' CTIM-76 Shows 29% Response Rate in Late-Stage Ovarian Cancer Trial
Event summary
- CTIM-76 achieved a 29% confirmed overall response rate in platinum-resistant ovarian cancer patients with a median of 7 prior therapies.
- Cytokine Release Syndrome (CRS) was limited to Grade 1 in 11% of patients, suggesting a favorable safety profile.
- Pharmacokinetic data supports exploring a Q3W dosing schedule in the second half of 2026.
- CTIM-76 has received FDA Fast Track Designation for platinum-resistant ovarian cancer.
The big picture
Context Therapeutics' positive interim data for CTIM-76 highlights the potential of T cell engaging bispecific antibodies in treating late-stage solid tumors. The 29% response rate in heavily pretreated ovarian cancer patients suggests a promising new option in a space with limited therapeutic advances. The favorable safety profile and potential for Q3W dosing could differentiate CTIM-76 in a competitive oncology market.
What we're watching
- Dosing Optimization
- Whether the Q3W dosing schedule will maintain efficacy while improving convenience for patients.
- Regulatory Pathway
- The pace at which FDA Fast Track Designation will accelerate CTIM-76's development timeline.
- Market Positioning
- How CTIM-76's 29% response rate positions it against existing and emerging therapies for platinum-resistant ovarian cancer.
Related topics